GSK confirms that Bexsero (meningococcal B vaccine) will be available for purchase in Australia next week
01 June 2017
GSK has increased supply by an additional 200,000 doses of Bexsero (meningococcal B vaccine) which can be ordered by wholesalers, pharmacies and GP surgeries over the coming days.
The doses will be available towards the end of next week and we expect they will go a long way to addressing the current demand.
We understand it has been distressing for parents who have wanted to help protect their children against meningococcal B disease but haven’t been able to access the vaccine.
The additional doses are being made available following an update to the Australian licence extending the shelf life to 36 months. This allowed increased supply of GSK’s meningococcal B vaccine to the Australian market.
There continues to be a global increase in demand for meningococcal B vaccine which is reflected in Australia as well.
Families should speak to their healthcare professional for advice and can expect to pay in the range of $120-140 per dose for the meningococcal B vaccine, depending on which pharmacy they visit.
Please visit the TGA website for ongoing updates to supply.
For more information, please contact GSK medical information on 1800 033 109 or visit Bexsero Consumer Medicine Information